Your labels? FDA wants to keep testing how you read them
Ever wonder why you grab one thing off the shelf and not another? The FDA is asking to keep testing how you actually read food labels.
By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation

Key points
- FDA asked OMB on September 11, 2026, to renew a generic qualitative research clearance that includes food and dietary supplements.
- The supplied FDA notice does not change a label, menu, ingredient rule, grocery price, farm practice or freight cost.
- No company, trade group, lobbyist, contract recipient, award amount or ownership interest is identified in the sole record provided.
- OMB’s disposition of the information-collection request is the next documented institutional gate; the supplied record gives no decision or comment-close date.
Picture the ordinary grocery aisle dilemma: you stand in front of a shelf reading a package, compare two products, and either drop one in your cart or give up and order takeout. A Sept. 11 filing from the Food and Drug Administration won't change that package tomorrow, set prices or ban an ingredient. But it asks the White House Office of Management and Budget to renew a tool FDA uses to ask focus groups and interviewees what they think about food labels, dietary supplements and cosmetics.
The filing touches how food information gets from federal agencies to supermarket shelves and public health campaigns. It does not alter restaurant menus, shipping costs, farm production or grocery bills.
In the Federal Register notice dated Sept. 11, 2026, FDA submitted a request for OMB review of a generic clearance titled "Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Other Products Regulated by FDA." A generic clearance is paperwork authorization for a category of small, qualitative research collections, rather than approval for one specific survey or new food rule.
That distinction matters. The agency is seeking capacity to listen before it acts, not authority in this notice to rewrite a Nutrition Facts panel or tell a restaurant what to put on its menu board. But research on whether consumers understand food information is part of the government's upstream machinery for future food policy. That machinery carries a quantifiable cost, measured in the time the public donates to focus groups and interviews.
FDA wants that research tool available. The record does not establish what future policies, if any, will result. Who holds the decision lever
FDA is the agency requesting the clearance, and OMB must approve or disapprove the information collection request. FDA's practical power under this clearance is to conduct qualifying qualitative social and behavioral research on products it regulates once OMB approves the generic process.
The filing puts the immediate decision inside OMB rather than the grocery aisle. FDA can use consumer research to understand messages, perceptions and behaviors regarding FDA-regulated products. It cannot use this notice alone to impose a new food label, change a recipe, collect a fee from a restaurant or alter a shelf price.
The filing is an information-collection action under the Paperwork Reduction Act. That law's paperwork gate decides whether an agency may collect information in the described way. FDA's notice identifies the request as a submission for OMB review and a comment request, placing OMB at the approval point.
FDA describes the subject as qualitative data supporting social and behavioral research for food, dietary supplements, cosmetics and other products under its jurisdiction. The agency stated in the filing that the purpose of this research is to "explore a variety of topics with consumers and other constituents to help design effective health and safety communications." The notice specifies the methods FDA may use under the clearance, including individual in-depth interviews, focus groups and group discussions conducted in person, by telephone or online, as reported by Federal Register.
The research will explore issues such as consumer understanding of food labeling, beliefs about diet and disease, and responses to public health messaging. For anyone buying groceries, the nearest link is comprehension. If FDA studies how people receive food-related information, the potential downstream impact includes the messaging on product packages or online grocery listings.
The record does not identify a specific label claim, nutrient, additive, food company, retailer, restaurant chain or dietary guideline under study. The notice is broad by design, and generic paperwork clearance is not a final decision about a particular box, bottle, menu board or delivery bill. A routine paper trail
The Sept. 11 notice shows FDA seeking OMB review for the generic research clearance. This is an extension of an existing authority rather than a request for new power.
The notice identifies the clearance by its OMB Control Number, 0910-0857. An OMB Control Number is a unique identifier assigned to a federally sponsored information collection approved under the Paperwork Reduction Act. This number and the agency's description of the action as an "extension" confirm the request continues a pre-existing research program.
The timeline for this authority stretches back several years. FDA's filing states that OMB granted the current approval for this clearance on May 19, 2020. Under the Paperwork Reduction Act, such approvals are typically valid for three years. The 2026 filing represents at least the second time FDA has sought to renew this specific research authority since its initial approval.
FDA first obtained the clearance in 2020, used it, and is now seeking to extend it again. The Sept. 11 filing documents the latest step in an ongoing administrative process. The cost is measured in hours
While the Federal Register notice contains no contract values or lobbying expenditures, it contains figures quantifying the clearance's public cost. The Paperwork Reduction Act requires federal agencies to estimate the "burden" an information collection imposes on the public. This burden is measured in hours spent responding rather than dollars spent on contracts.
FDA's filing presents this calculation as a required part of its request to OMB. These figures represent the government's formal estimate of the time commitment it asks from citizens, healthcare professionals and industry representatives.
FDA projects a total of 30,000 respondents per year. These participants come from the general public, healthcare fields and private industry.
The notice estimates that each of the 30,000 respondents will participate in one session per year, lasting an average of 0.75 hours, or 45 minutes.
Multiplying the number of respondents by the time per response, FDA calculates a total annual burden of 22,500 hours. This number represents the total estimated time participants will spend on this research each year if the clearance is approved and fully utilized. The filing does not break down how many hours will go specifically to food research versus cosmetics or other regulated goods. Where this touches your food
FDA's notice explicitly includes food in the research clearance's scope. That puts grocery store shelves at the most direct point of contact. A shopper's interaction with package claims, including how those claims are understood, fits squarely into social and behavioral research.
"Can support" is not "will change." The notice does not say FDA will test a front-of-pack statement, the Nutrition Facts panel, allergen wording, ingredient lists, dietary supplement claims, marketing aimed at young adults or restaurant menu disclosures. It names a clearance category rather than a finished rule.
There is no documented basis to claim grocery bills will rise, labels will change next week, or specific brands will gain an advantage. No fee, compliance cost, price estimate or product mandate appears in the FDA notice.
Restaurants and commercial kitchens sit in the broader path from food information to dining choices, but the notice does not identify restaurant meals, menu labeling, kitchen staffing, delivery platforms or food-service operators as research subjects. It assigns no new tasks to restaurants.
The same limits apply to logistics, shipping and agriculture. Nothing in the notice concerns trucking, port operations, warehousing, fuel, refrigeration, labor or distribution. Farms are similarly untouched; the filing does not alter crop standards, agricultural inputs or farm payments.
Public health and diets are the downstream endpoints. Understanding how people process food messaging can inform agency efforts around consumer education and population health. Still, the notice does not adopt new dietary guidance or alter federal health spending.
A clearance is a administrative clipboard, not a meal plan. It enables FDA to ask questions, but it does not dictate answers or impose immediate food policy on shoppers. Who benefits from the clearance
The primary beneficiary named in the filing is FDA itself. If OMB grants the clearance, FDA maintains a streamlined mechanism for qualifying qualitative research collections tied to food, dietary supplements, cosmetics and other regulated items. This avoids the administrative delay of seeking individual OMB approvals for every small focus group or interview series.
Generic clearances allow agencies to gather consumer data more efficiently to inform regulatory and communication work. But the record does not detail how many individual studies FDA will run, the topics it will select, or the specific policies it will craft later.
The public could benefit if better qualitative research leads to clearer, more useful food labeling. The record itself does not quantify a direct consumer benefit.
The record names FDA as the requesting agency and OMB as the reviewing body, with no private companies, trade groups, contractors or lobbyists listed as applicants or beneficiaries. The public filing documents an agency request rather than private industry influence. Proven facts and hard limits
FDA published a Federal Register notice on Sept. 11, 2026, asking OMB to extend a generic clearance for qualitative social and behavioral research. The clearance carries OMB Control Number 0910-0857 and was first approved on May 19, 2020. The research scope includes food and dietary supplements, with FDA as the requesting agency and OMB as the decision-maker.
The notice establishes the estimated public time cost. FDA projects an annual burden of 22,500 hours based on 30,000 respondents spending an average of 45 minutes each. This represents an administrative request for research authority rather than a final food-labeling rule or menu mandate. The record contains no price impact, corporate product list, lobbying disclosure or contract award.
The filing does not prove FDA will alter grocery labels tomorrow, change restaurant menus, increase food costs, or restrict specific additives or supplements. The burden estimate of 22,500 hours reflects potential capacity rather than a guarantee that every hour will be used, nor does it detail how those hours will be divided among food, cosmetics or other categories.
An agency filing records administrative activity. In this case, it tracks FDA's attempt to preserve a research tool. Treating this request as proof that a new food policy has been finalized would misread the paper trail.
Consumer research functions as an upstream mechanism. Federal agencies often need a framework to gather public feedback before proposing, testing or communicating food policy. This notice concerns that preliminary tool rather than the checkout total at your local market. What happens next
FDA's Sept. 11 notice opened a 60-day window for public comment, setting a comment deadline of Nov. 10, 2026. After that date, OMB will review the agency's request alongside any public comments before rendering a decision.
OMB can approve, disapprove or request modifications to the information collection request through the Paperwork Reduction Act process. The outcome will be recorded under OMB Control Number 0910-0857.
If OMB approves the clearance, the next development to watch will be the specific studies FDA announces under its authority. Individual focus groups or survey plans will signal which packaging claims, supplement labels or health messages the agency intends to evaluate.
Until then, the filing shows that FDA wants to keep its research tool available for studying consumer perceptions of food and other regulated products. Watch OMB's decision on control number 0910-0857, followed by any specific FDA research topics announced under that authority. That is where administrative paperwork turns into research that could eventually shape what appears on package labels at the grocery store.